Advised on Sale of Majority StakeHealthcare
Acquired majority stake of Business Operations
Miacom Diagnostics develops highly innovative product lines for medical diagnostics for clinics, protected by a series of international patents. Inveni Life Sciences Fund has acquired a majority stake of Miacom and brought in fresh money to accelerate further development and international market launch of these product lines.
Specialist of products for molecular identification and characterization of microorganisms. Bacterial diagnostic for identification and antibiotic susceptibility testing. Owner of a highly innovative platform technology for rapid pathogen testing. Proprietary technology for microbial pathogen diagnostics using a novel class of DNA-probes for “Fluorescence in situ hybridization (FISH)” assays. Product line I: Identification (ID) of microbial pathogens; Product line II: Identification of pathogens with parallel antibiotic susceptibility testing (AST/ID).
A venture capital fund with offices in Finland and Germany. Some € 30million under management to invest in early to growth–stage life science (pharma and medtech) companies in Northern and Central Europe. With its experienced team, Inveni is a highly engaged investor in its portfolio companies.
IMAP initiated the transaction on behalf of MIACOM Diagnostics GmbH, communicated with potential investors, structured and handled the transaction in all its phases.